1887
Rapid communication Open Access
Like 0

Abstract

Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lübeck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISAs, respectively. Of 39 coronavirus disease patients, 13 were IgG and IgA positive and 11 IgA alone at sampling. IgGs and IgAs were respectively detected at a median of 12 and 11 days after symptom onset.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2020.25.18.2000603
2020-05-07
2020-05-29
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2020.25.18.2000603
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/25/18/eurosurv-25-18-3.html?itemId=/content/10.2807/1560-7917.ES.2020.25.18.2000603&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK – ninth update, 23 April 2020. Stockholm: ECDC; 2020. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-assessment-coronavirus-disease-2019-ninth-update-23-april-2020.pdf
  2. Eurosurveillance Editorial Team. Latest updates on COVID-19 from the European Centre for Disease Prevention and Control. Euro Surveill. 2020;25(6):2002131. PMID: 32070466 
  3. World Health Organization (WHO). Coronavirus disease (COVID-19) Pandemic. Geneva: WHO. [Accessed 28 Mar 2020]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
  4. Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, et al. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill. 2020;25(9):2000178.  https://doi.org/10.2807/1560-7917.ES.2020.25.9.2000178  PMID: 32156327 
  5. World Health Organization (WHO). Laboratory testing of 2019 novel coronavirus (‎‎‎‎‎‎‎‎‎‎‎‎2019-nCoV)‎‎‎‎‎‎‎‎‎‎‎‎ in suspected human cases: interim guidance, 17 January 2020. Geneva: WHO; 17 Jan 2020.
  6. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045.  https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045  PMID: 31992387 
  7. Okba NMA, Muller MA, Li W, Wang C, Geurtsvankessel CH, Corman VM, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv. preprint doi:
  8. Amanat F, Nguyen T, Chromikova V, Strohmeier S, Stadlbauer D, Javier A, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv. preprint doi:  https://doi.org/10.1101/2020.03.17.20037713 
  9. Siddiqi HK, Mehra MR. COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. J Heart Lung Transplant. 2020;39(5):405-7.  https://doi.org/10.1016/j.healun.2020.03.012 
  10. World Health Organization (WHO). Global surveillance for COVID-19 caused by human infection with COVID-19 virus. Geneva: WHO; 20 Mar 2020. Available from: https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov)
  11. Okba NMA, Raj VS, Widjaja I, GeurtsvanKessel CH, de Bruin E, Chandler FD, et al. Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections. Emerg Infect Dis. 2019;25(10):1868-77.  https://doi.org/10.3201/eid2510.190051  PMID: 31423970 
  12. Nicastri E, D’Abramo A, Faggioni G, De Santis R, Mariano A, Lepore L, et al. On Behalf Of Inmi And The Italian Army Covid-Study Groups. Coronavirus disease (COVID-19) in a paucisymptomatic patient: epidemiological and clinical challenge in settings with limited community transmission, Italy, February 2020. Euro Surveill. 2020;25(11):2000230.  https://doi.org/10.2807/1560-7917.ES.2020.25.11.2000230  PMID: 32209164 
  13. Haveri A, Smura T, Kuivanen S, Österlund P, Hepojoki J, Ikonen N, et al. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Euro Surveill. 2020;25(11):2000266.  https://doi.org/10.2807/1560-7917.ES.2020.25.11.2000266  PMID: 32209163 
/content/10.2807/1560-7917.ES.2020.25.18.2000603
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error